Leqvio
Aug 07, 2026
The Emergence of Oral PCSK9 Inhibitors: A Transformative Innovation in Lipid Management
Summary For nearly a decade, PCSK9 inhibitors have been highly effective at lowering LDL cholesterol, but their growth has been limited by the need for injections. The U.S. FDA approval of Merck’s LIPFENDRA (enlicitide) changes that by introducing the first oral PCSK9 inhibitor, marking a major shift from ne...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
